Canaccord Genuity Maintains a 'Buy' on NPS Pharmaceuticals (NPSP); Highlights From Analyst Event
Tweet
Share
E-mailGet Alerts NPSP Hot Sheet
Price: $45.97 --0%
Rating Summary:
8 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
8 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on NPS Pharmaceuticals Inc. (NASDAQ: NPSP) price target of $16.00.
Analyst, Salveen Richter, said, "NPSP hosted an analyst event where Dr. Bilezikian of Columbia University reviewed the Natpara P3 REPLACE data in hypoparathyroidism (N=134. 2:1 Natpara vs. placebo) presented at ENDO. While Natpara met its primary endpoint (53.3% in the Natpara arm had ≥50% reduction in oral calcium and vitamin D with stable serum calcium levels vs. 2.3% in placebo at 24 weeks, p<0.001) and secondary endpoint (42.9% Natpara arm had vitamin D independence with low-dose calcium vs. 5.4% in placebo), as detailed in the abstract, new data showed a trend in a tertiary endpoint (33% in the Natpara arm showed clinical symptomatology vs. 41% in placebo) and a clean safety profile. Net-net, post a positive CHMP recommendation for Gattex approval in short bowel syndrome on Friday, the near-term focus remains on the likely GI Drugs Advisory Panel in 2H12 (we expect a delay in the September 30 PDUFA)."
For an analyst ratings summary and ratings history on NPS Pharmaceuticals Inc. click here. For more ratings news on NPS Pharmaceuticals Inc. click here.
Shares of NPS Pharmaceuticals Inc. closed at $8.10 yesterday.
Analyst, Salveen Richter, said, "NPSP hosted an analyst event where Dr. Bilezikian of Columbia University reviewed the Natpara P3 REPLACE data in hypoparathyroidism (N=134. 2:1 Natpara vs. placebo) presented at ENDO. While Natpara met its primary endpoint (53.3% in the Natpara arm had ≥50% reduction in oral calcium and vitamin D with stable serum calcium levels vs. 2.3% in placebo at 24 weeks, p<0.001) and secondary endpoint (42.9% Natpara arm had vitamin D independence with low-dose calcium vs. 5.4% in placebo), as detailed in the abstract, new data showed a trend in a tertiary endpoint (33% in the Natpara arm showed clinical symptomatology vs. 41% in placebo) and a clean safety profile. Net-net, post a positive CHMP recommendation for Gattex approval in short bowel syndrome on Friday, the near-term focus remains on the likely GI Drugs Advisory Panel in 2H12 (we expect a delay in the September 30 PDUFA)."
For an analyst ratings summary and ratings history on NPS Pharmaceuticals Inc. click here. For more ratings news on NPS Pharmaceuticals Inc. click here.
Shares of NPS Pharmaceuticals Inc. closed at $8.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Bernstein SocGen on Meta Platforms Inc. (META): 'Risk-reward remains attractive'
- Beike (BEKE) PT Raised to $23 at Morgan Stanley
Create E-mail Alert Related Categories
Analyst Comments, FDARelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
